{ "schemaVersion": 1, "organisationId": "O-e70da162eed5455f9bbe8fdbf7fc34ca", "slug": "ascendis-pharma-a-s", "name": "Ascendis Pharma A/S", "updatedAt": "2026-10-02T12:26:03.238505Z", "sections": [ { "type": "OVERVIEW", "text": "Ascendis Pharma A/S is a global biopharmaceutical company focused on developing medicines for unmet medical needs, particularly in endocrinology and rare diseases. Its stated mission is to make a meaningful difference for patients, guided by “Patients, Science, and Passion.” Its proprietary TransCon platform is designed to enable controlled release of medicines over time. [P153391766][P153391050]\n\nIts defining products include SKYTROFA for growth hormone deficiency and YORVIPATH for adult hypoparathyroidism; in 2026, the FDA approved YUVIWEL for children with achondroplasia. The company’s commercial reach includes the United States, Europe and Japan, alongside licensing partnerships in Japan and Greater China. [P153391803][P153391855][https://investors.ascendispharma.com/news-releases/news-release-details/fda-approves-once-weekly-yuviwelr-navepegritide-children]\n\nFor scale, Ascendis reported €684 million in product revenue for FY2025 and 1,189 employees at year-end 2025. [P153391766][https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-pharma-reports-fourth-quarter-and-full-year-2025]\n[P153391766][P153391050][P153391803][P153391855][https://investors.ascendispharma.com/news-releases/news-release-details/fda-approves-once-weekly-yuviwelr-navepegritide-children][https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-pharma-reports-fourth-quarter-and-full-year-2025]", "updatedAt": "2026-10-02T12:26:03.238505Z" }, { "type": "PRODUCTS", "text": "Ascendis Pharma’s marketed products include SKYTROFA® (lonapegsomatropin-tcgd), a once-weekly, long-acting growth hormone replacement therapy for growth failure associated with growth hormone deficiency in children and for adults requiring growth hormone replacement; its authorized pediatric age ranges vary by market. [P153391805] YORVIPATH® (palopegteriparatide) is a treatment for adults with hypoparathyroidism; its U.S. presentation uses a pen-injector. [P153391803][P153391348] YUVIWEL® (navepegritide) is a once-weekly treatment approved by the FDA in 2026 to increase linear growth in children aged two years and older with achondroplasia and open growth plates. [https://investors.ascendispharma.com/news-releases/news-release-details/fda-approves-once-weekly-yuviwelr-navepegritide-children][https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219164Orig1s000lbl.pdf]\n\nThe company’s TransCon technology links a parent drug to a carrier through a linker; following administration, the prodrug is designed to release the unmodified parent drug over time, extending exposure while preserving its mode of action. [P153391050] Development programs include additional TransCon hGH indications and TransCon CNP research in other patient groups and indications. The oncology pipeline has included TransCon IL-2 β/γ (onvapegleukin alfa), a long-acting IL-2 variant designed for systemic exposure, and an investigational TransCon TLR7/8 Agonist prodrug of resiquimod designed for intratumoral delivery. [P153391807][P153391809]\n\nIn the second quarter of 2026, reported product revenue was €315 million: €252 million from YORVIPATH, €55 million from SKYTROFA, and €8 million from YUVIWEL—approximately 80%, 17%, and 3% of product revenue, respectively, based on those reported amounts. [https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-pharma-reports-second-quarter-2026-financial-results]\n[P153391805][P153391803][P153391348][https://investors.ascendispharma.com/news-releases/news-release-details/fda-approves-once-weekly-yuviwelr-navepegritide-children][https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219164Orig1s000lbl.pdf][P153391050][P153391807][P153391809][https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-pharma-reports-second-quarter-2026-financial-results][https://investors.ascendispharma.com/news-releases/news-release-details/fda-approves-once-weekly-yuviwelr-navepegritide-children][https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219164Orig1s000lbl.pdf][https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-pharma-reports-second-quarter-2026-financial-results]", "updatedAt": "2026-10-02T12:26:03.238505Z" }, { "type": "GEOGRAPHY", "text": "Ascendis Pharma A/S is headquartered in Hellerup, Denmark, and has offices and research and development facilities in Denmark, Germany, and the United States. Its commercial presence includes the United States and Europe, with sales or representative offices in Germany, France, Spain, Italy, Switzerland, Portugal, and the United Kingdom. The company reports that it relies on contract manufacturers and does not own product-manufacturing facilities. [P153391760][P153392324]\n\nFor 2025, reported revenue was €546.388 million from the United States (75.9% of total), €120.946 million from Europe (16.8%), and €52.798 million from the rest of the world (7.3%). Denmark accounted for €12.9 million; the filing does not provide further country-level sales detail. [T17671231][P153393304][P153393306] Its listed wholly owned subsidiaries are domiciled in Denmark, Germany, the United States, the United Kingdom, Spain, France, Italy, Sweden, Switzerland, Belgium, and Portugal. The company also has an associate, VISEN Pharmaceuticals, which holds rights in Greater China. [T17671259][P153391053]\n[P153391760][P153392324][T17671231][P153393304][P153393306][T17671259][P153391053]", "updatedAt": "2026-10-02T12:26:03.238505Z" }, { "type": "SEGMENTS", "text": "Ascendis Pharma reports one business unit and does not report separate operating or reportable business segments. Its product and geographic revenue disclosures are disaggregations, not formally reported segments. [P153393344]\n\nFor the six months ended June 30, 2026, product revenue was approximately €449 million for YORVIPATH (about 80.8% of product revenue), €99 million for SKYTROFA (17.8%), and €8 million for YUVIWEL (1.4%); percentages are calculated from the reported amounts. YORVIPATH is for hypoparathyroidism, SKYTROFA is a growth-hormone therapy, and YUVIWEL is for achondroplasia. [https://investors.ascendispharma.com/static-files/2626f3d0-042b-4d2d-9bbb-8fa2270c02c1] [https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm] [https://investors.ascendispharma.com/news-releases/news-release-details/fda-approves-once-weekly-yuviwelr-navepegritide-children]\n[P153393344][https://investors.ascendispharma.com/static-files/2626f3d0-042b-4d2d-9bbb-8fa2270c02c1][https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm][https://investors.ascendispharma.com/news-releases/news-release-details/fda-approves-once-weekly-yuviwelr-navepegritide-children]", "updatedAt": "2026-10-02T12:26:03.238505Z" }, { "type": "HISTORY", "text": "Ascendis Pharma was founded in December 2007 by Jan Møller Mikkelsen, who became its President and CEO. [P153392464] In January 2015, the company priced its initial public offering and began trading on Nasdaq. [https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-pharma-announces-pricing-initial-public-offering]\n\nIn 2018, Ascendis formed VISEN Pharmaceuticals, granting it exclusive rights in Greater China to develop and commercialize three TransCon candidates in exchange for a 50% ownership interest. [P153392077] A key product milestone followed in August 2021, when the FDA approved TransCon hGH, marketed as SKYTROFA, for children with growth hormone deficiency; the product launched in the United States later that year. [P153390741][P153391805] SKYTROFA received European Commission authorization in January 2022, and its first EU commercial launch was in Germany in 2023. [P153390741][P153391805]\n\nThe European Commission authorized TransCon PTH, marketed as YORVIPATH, in November 2023. [P153390741] The FDA approved it for adults with hypoparathyroidism in August 2024, followed by its U.S. launch in December. [P153391803] In 2025, Ascendis reported that VISEN had listed on the Hong Kong Stock Exchange, with Ascendis retaining a 39.2% stake, and the FDA expanded SKYTROFA’s U.S. indication to adults with growth hormone deficiency. [P153392079][P153390741]\n[P153392464][P153392077][P153390741][P153391805][P153391803][P153392079][https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-pharma-announces-pricing-initial-public-offering]", "updatedAt": "2026-10-02T12:26:03.238505Z" } ], "sources": [ { "id": "P153391766", "href": "https://app.finbar.com/go?id=P153391766", "label": "Ascendis Pharma A/S — Full financial report (2025 Y)", "documentId": "D-16c153575d7b447a839cb8381ba583fe" }, { "id": "P153391050", "href": "https://app.finbar.com/go?id=P153391050", "label": "Ascendis Pharma A/S — Full financial report (2025 Y)", "documentId": "D-16c153575d7b447a839cb8381ba583fe" }, { "id": "P153391803", "href": "https://app.finbar.com/go?id=P153391803", "label": "Ascendis Pharma A/S — Full financial report (2025 Y)", "documentId": "D-16c153575d7b447a839cb8381ba583fe" }, { "id": "P153391855", "href": "https://app.finbar.com/go?id=P153391855", "label": "Ascendis Pharma A/S — Full financial report (2025 Y)", "documentId": "D-16c153575d7b447a839cb8381ba583fe" }, { "id": "https://investors.ascendispharma.com/news-releases/news-release-details/fda-approves-once-weekly-yuviwelr-navepegritide-children", "href": "https://investors.ascendispharma.com/news-releases/news-release-details/fda-approves-once-weekly-yuviwelr-navepegritide-children", "label": "investors.ascendispharma.com" }, { "id": "https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-pharma-reports-fourth-quarter-and-full-year-2025", "href": "https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-pharma-reports-fourth-quarter-and-full-year-2025", "label": "investors.ascendispharma.com" }, { "id": "P153391805", "href": "https://app.finbar.com/go?id=P153391805", "label": "Ascendis Pharma A/S — Full financial report (2025 Y)", "documentId": "D-16c153575d7b447a839cb8381ba583fe" }, { "id": "P153391348", "href": "https://app.finbar.com/go?id=P153391348", "label": "Ascendis Pharma A/S — Full financial report (2025 Y)", "documentId": "D-16c153575d7b447a839cb8381ba583fe" }, { "id": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219164Orig1s000lbl.pdf", "href": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219164Orig1s000lbl.pdf", "label": "www.accessdata.fda.gov" }, { "id": "P153391807", "href": "https://app.finbar.com/go?id=P153391807", "label": "Ascendis Pharma A/S — Full financial report (2025 Y)", "documentId": "D-16c153575d7b447a839cb8381ba583fe" }, { "id": "P153391809", "href": "https://app.finbar.com/go?id=P153391809", "label": "Ascendis Pharma A/S — Full financial report (2025 Y)", "documentId": "D-16c153575d7b447a839cb8381ba583fe" }, { "id": "https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-pharma-reports-second-quarter-2026-financial-results", "href": "https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-pharma-reports-second-quarter-2026-financial-results", "label": "investors.ascendispharma.com" }, { "id": "P153391760", "href": "https://app.finbar.com/go?id=P153391760", "label": "Ascendis Pharma A/S — Full financial report (2025 Y)", "documentId": "D-16c153575d7b447a839cb8381ba583fe" }, { "id": "P153392324", "href": "https://app.finbar.com/go?id=P153392324", "label": "Ascendis Pharma A/S — Full financial report (2025 Y)", "documentId": "D-16c153575d7b447a839cb8381ba583fe" }, { "id": "T17671231", "href": "https://app.finbar.com/go?id=T17671231", "label": "Ascendis Pharma A/S — Full financial report (2025 Y)", "documentId": "D-16c153575d7b447a839cb8381ba583fe" }, { "id": "P153393304", "href": "https://app.finbar.com/go?id=P153393304", "label": "Ascendis Pharma A/S — Full financial report (2025 Y)", "documentId": "D-16c153575d7b447a839cb8381ba583fe" }, { "id": "P153393306", "href": "https://app.finbar.com/go?id=P153393306", "label": "Ascendis Pharma A/S — Full financial report (2025 Y)", "documentId": "D-16c153575d7b447a839cb8381ba583fe" }, { "id": "T17671259", "href": "https://app.finbar.com/go?id=T17671259", "label": "Ascendis Pharma A/S — Full financial report (2025 Y)", "documentId": "D-16c153575d7b447a839cb8381ba583fe" }, { "id": "P153391053", "href": "https://app.finbar.com/go?id=P153391053", "label": "Ascendis Pharma A/S — Full financial report (2025 Y)", "documentId": "D-16c153575d7b447a839cb8381ba583fe" }, { "id": "P153393344", "href": "https://app.finbar.com/go?id=P153393344", "label": "Ascendis Pharma A/S — Full financial report (2025 Y)", "documentId": "D-16c153575d7b447a839cb8381ba583fe" }, { "id": "https://investors.ascendispharma.com/static-files/2626f3d0-042b-4d2d-9bbb-8fa2270c02c1", "href": "https://investors.ascendispharma.com/static-files/2626f3d0-042b-4d2d-9bbb-8fa2270c02c1", "label": "investors.ascendispharma.com" }, { "id": "https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm", "href": "https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm", "label": "www.sec.gov" }, { "id": "P153392464", "href": "https://app.finbar.com/go?id=P153392464", "label": "Ascendis Pharma A/S — Full financial report (2025 Y)", "documentId": "D-16c153575d7b447a839cb8381ba583fe" }, { "id": "https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-pharma-announces-pricing-initial-public-offering", "href": "https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-pharma-announces-pricing-initial-public-offering", "label": "investors.ascendispharma.com" }, { "id": "P153392077", "href": "https://app.finbar.com/go?id=P153392077", "label": "Ascendis Pharma A/S — Full financial report (2025 Y)", "documentId": "D-16c153575d7b447a839cb8381ba583fe" }, { "id": "P153390741", "href": "https://app.finbar.com/go?id=P153390741", "label": "Ascendis Pharma A/S — Full financial report (2025 Y)", "documentId": "D-16c153575d7b447a839cb8381ba583fe" }, { "id": "P153392079", "href": "https://app.finbar.com/go?id=P153392079", "label": "Ascendis Pharma A/S — Full financial report (2025 Y)", "documentId": "D-16c153575d7b447a839cb8381ba583fe" } ] }